Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Stage 2 hypertension (SBP/DBP ≥ 140/90 mmHg) showed significant associations with cardiovascular disease and all-cause mortality, while elevated blood pressure (SBP 120-129 mmHg and DBP < 80 mmHg) showed null associations.
|
31288541 |
2020 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Epidemiological studies reported an inconsistent association between stage 1 hypertension (SBP 130-139 mmHg or DBP 80-89 mmHg) defined by the 2017 American College of Cardiology/American Heart Association hypertension guidelines and cardiovascular disease (CVD) events.
|
31790053 |
2020 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The association between lower SBP and lesser risk of CVD may instead suggest a beneficial effect of lower SBP.
|
31188164 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Risk of total CVDs, MI, and stroke was increased with low-range prehypertension (low-range: SBP 120-129 mmHg and/or DBP 80-84 mmHg) versus normal BP - RR 1.42 (95% CI 1.29-1.55), 1.43 (1.10-1.86), and 1.52 (1.27-1.81), respectively - and risk of total CVDs, CHD, MI, and stroke was increased with high-range prehypertension (high-range: SBP 130-139 mmHg and/or DBP 85-89 mmHg) - RR 1.81 (95% CI 1.56-2.10), 1.65 (1.13-2.39), 1.99 (1.59-2.50), and 1.99 (1.68-2.36), respectively.
|
31335511 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Testosterone and its binding protein sex hormone-binding globulin have been associated with cardiovascular disease and dysglycaemia.
|
30567457 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Eligible participants (N = 50, mean age 74 ± 7 years, 34% men, 26% with history of cardiovascular disease) had higher SBP during the anesthesiologic than the cardiological evaluation (157 ± 23 vs. 144 ± 18 mmHg, P < 0.001), and the former levels were almost identical to those clinically measured just before surgery.
|
30950973 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Newly defined stage 1 hypertension and elevated BP were associated with increased risk of incident CVD, whereas long-term changes of SBP and DBP had effects of varying degree on CVD incidence.
|
31116159 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
A positive dose-response relationship of daily walking duration with quartiles of SHBG was seen after adjustment for age, sex, history of cardiovascular diseases, diabetes, smoking, γ-glutamyl transferase, and C-reactive protein (p for trend = .010).
|
30676188 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We analyzed OH measurements from the Action to Control Cardiovascular Risk in Diabetes BP trial, which evaluated two blood pressure (BP) goals (systolic BP [SBP] < 120 mm Hg vs. SBP < 140 mm Hg) and incident CVD among adults with diabetes and hypertension.
|
30715100 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In the dipping group, only night-day ratio of SBP was significantly associated with CVD, with an odds ratio (OR) of 1.09 (95% confidence interval (CI) of 1.02-1.34).
|
30899285 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
If identified, such changes may have important clinical relevance, particularly, as low sex hormone binding globulin (SHBG) and follicle stimulating hormone (FSH) are known to promote metabolic and cardiovascular disease in women.
|
30339729 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Median HbA<sub>1c</sub> overall was 55 mmol/mol (7.2%), median SBP was 132 mmHg, median total cholesterol was 4.1 mmol/l and mean BMI was 32 kg/m<sup>2</sup><sub>.</sub> Overall two-thirds (65% of men, 68% of women) have two or more of the following CVD risk factor thresholds: HbA<sub>1c</sub> ≥ 53 mmol/mol (7%), SBP > 130 mmHg or DBP > 80 mmHg, total cholesterol ≥ 5 mmol/l or BMI ≥ 30 kg/m<sup>2</sup> , or were currently smoking.
|
30246473 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
The certainty of the evidence was moderate for SBP and low for CVD incidence and ranged from very low to moderate for the secondary outcomes.
|
30764511 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Neither SHBG nor TT was significantly associated with all-age CVD mortality [hazard ratio (HR), 0.69; 95% CI, 0.29 to 1.63; P = 0.40; and HR, 0.60; 95% CI, 0.28 to 1.26; P = 0.18, respectively].
|
31390027 |
2019 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
We used cross-sectional data from 2913 men aged 76.7 ± 3.2 years with morning blood samples assayed for T, DHT, E2 (mass spectrometry), and sex hormone-binding globulin (SHBG, immunoassay), to correlate sex hormones with LTL measured using PCR and expressed as T/S ratio in multivariable linear regression models adjusted for age, cardiometabolic risk factors and cardiovascular disease history.
|
30561819 |
2019 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our findings support a SBP treatment target of 140 mmHg and suspect no risk reduction attenuation on CVD for lower SBP targets (<120 or <130 mmHg) for most patients with uncomplicated T2DM.
|
29592967 |
2018 |
Cardiovascular Diseases
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Total estradiol (E<sub>2</sub>), total testosterone (TT), androstenedione (AD), dehydroepiandrosterone (DHEA), dehydroepiandrosterone sulfate (DHEAS), sex hormone-binding globulin (SHBG) and NT-proBNP were assessed in 4112 postmenopausal women free of cardiovascular diseases from the prospective population-based Rotterdam Study.
|
29551255 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Investigate relations of mass spectrometry-assessed estrone (E1), E2, and T and SHBG and subclinical CVD in women.
|
29788255 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Adjusted cubic spline analysis showed significant nonlinear but different association between SBP and CVD mortality among diabetes mellitus (U-shaped) and NON-DM (J-shaped).
|
28800042 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Background Both sex hormone-binding globulin and central obesity have been found to be associated with metabolic and cardiovascular diseases.
|
29770358 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Linear, logistic, and Cox regression models assessed the association of top quartiles (P75) of serum testosterone, free androgen index (FAI), dehydroepiandrosterone, and androstenedione and sex hormone-binding globulin with coronary artery calcium, carotid intima-media thickness (IMT), pulse wave velocity, peripheral artery disease, and incidence of coronary heart disease (CHD), stroke, and CVD.
|
29408955 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
To explore the association between systolic and diastolic blood pressure (SBP and DBP respectively) and pulse pressure (PP) with cardiovascular disease (CVD) and mortality events among Iranian patients with prevalent CKD.
|
30111315 |
2018 |
Cardiovascular Diseases
|
0.100 |
AlteredExpression
|
group |
BEFREE |
AGHD = adult growth hormone deficiency; ASCVD = atherosclerotic cardiovascular disease; AUROC = area under the receiver operating characteristic curve; BMI = body mass index; CVAI = Chinese visceral adiposity index; CVD = cardiovascular disease; DBP = diastolic blood pressure; GH = growth hormone; GHRT = GH replacement therapy; HDL-C = high-density lipoprotein cholesterol; IGF-1 = insulin like factor-1; IGFBP-3 = insulin like factor binding protein-3; IR = insulin resistance; LAP = lipid accumulation product; MS = metabolic syndrome; SBP = systolic blood pressure; TC = total cholesterol; TG = triglycerides; VAI = visceral adiposity index; WC = waist circumference; WHR = waist-to-hip ratio.
|
29144802 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Furthermore, CR decreased blood pressure (SBP -8 ± 3 mmHg, P = 0.005; DBP -6 ± 2 mmHg, P < 0.001), total cholesterol (-13.6 ± 5.3 mg/dl, P = 0.001), and LDL-cholesterol (-12.9 ± 4.4 mg/dl, P = 0.005), and the 10-yr risk of CVD-disease was reduced by 30%.
|
29351490 |
2018 |
Cardiovascular Diseases
|
0.100 |
Biomarker
|
group |
BEFREE |
Additionally, participants with CVD had significantly higher central SBP and AIx@75 compared with those without CVD.
|
29049227 |
2017 |